REFERENCE
[1] Cummings M J, Baldwin M R, Abrams D, et al. Epidemiology,
clinical course, and outcomes of critically ill adults with COVID-19 in
New York City: a prospective cohort study [J]. The Lancet, 2020,
395(10239): 1763-70.
[2] Alroughani R, Al-hashel J, Abokalawa F, et al. COVID-19
vaccination in people with multiple sclerosis, real-life experience
[J]. Clinical Neurology and Neurosurgery, 2022 220.
[3] Ramasamy M N, Minassian A M, Ewer K J, et al. Safety and
immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
regimen in young and old adults (COV002): a single-blind, randomised,
controlled, phase 2/3 trial [J]. Lancet, 2021, 396(10267): 1979-93.
[4] Polack F P, Thomas S J, Kitchin N, et al. Safety and Efficacy of
the BNT162b2 mRNA Covid-19 Vaccine [J]. N Engl J Med, 2020, 383(27):
2603-15.
[5] Marsh E B, Kornberg M, Kessler K, et al. COVID-19 and
Vaccination in the Setting of Neurologic Disease: An Emerging Issue in
Neurology [J]. Neurology, 2021, 97(15): 720-8.
[6] Iranzo A. Sleep and neurological autoimmune diseases [J].
Neuropsychopharmacology, 2020, 45(1): 129-40.
[7] Gilhus N E, Verschuuren J J. Myasthenia gravis: subgroup
classification and therapeutic strategies [J]. Lancet Neurol, 2015,
14(10): 1023-36.
[8] Garjani A, Middleton R M, Hunter R, et al. COVID-19 is
associated with new symptoms of multiple sclerosis that are prevented by
disease modifying therapies [J]. Mult Scler Relat Disord, 2021, 52:
102939.
[9] Peng S, Tian Y, Meng L, et al. The safety of COVID-19 vaccines
in patients with myasthenia gravis: A scoping review [J]. Front
Immunol, 2022, 13: 1103020.
[10] Guimarães L E, Baker B, Perricone C, et al. Vaccines, adjuvants
and autoimmunity [J]. Pharmacol Res, 2015, 100: 190-209.
[11] Kaulen L D, Doubrovinskaia S, Mooshage C, et al. Neurological
autoimmune diseases following vaccinations against SARS-CoV-2: a case
series [J]. Eur J Neurol, 2022, 29(2): 555-63.
[12] Kong L, Wang X, Chen H, et al. Relapses after SARS-CoV-2
vaccination in patients with neuromyelitis optica spectrum disorder and
multiple sclerosis [J]. Mult Scler Relat Disord, 2022 IN-27 68:
104167.
[13] Farina A, Falso S, Cornacchini S, et al. Safety and
tolerability of SARS-Cov-2 vaccination in patients with myasthenia
gravis: A multicenter experience [J]. Eur J Neurol, 2022 IN-13,
29(8): 2505-10.
[14] Jovicevic V, Ivanovic J, Andabaka M, et al. COVID-19 and
vaccination against SARS-CoV-2 in patients with neuromyelitis optica
spectrum disorders [J]. Multiple Sclerosis and Related Disorders,
2022 IN-16, 57.
[15] Balduzzi S, Rucker G, Schwarzer G. How to perform a
meta-analysis with R: a practical tutorial [J]. Evid Based Ment
Health, 2019, 22(4): 153-60.
[16] Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in
patients with multiple sclerosis: What we have learnt by February 2021
[J]. Multiple Sclerosis Journal, 2021 IN-1, 27(6): 864-70.
[17] Ali sahraian M, Ghadiri F, Azimi A, et al. Adverse events
reported by Iranian patients with multiple sclerosis after the first
dose of Sinopharm BBIBP-CorV [J]. Vaccine, 2021 IN-2, 39(43):
6347-50.
[18] Briggs F, Mateen F, Schmidt H, et al. COVID-19 vaccine
reactogenicity in persons with multiple sclerosis [J]. Multiple
Sclerosis Journal, 2021 IN-3, 27(2_SUPPL): 768-9.
[19] Brunn J A, Dunietz G L, Romeo A R, et al. SARS-CoV-2 Infection
and Vaccination Outcomes in Multiple Sclerosis [J]. Neurology:
Clinical Practice, 2022 IN-4, 12(3): E14-E21.
[20] Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and
safety of mRNA COVID-19 vaccines in people with multiple sclerosis
treated with different disease-modifying therapies [J].
Neurotherapeutics, 2022 IN-5, 19(1): 325-33.
[21] Ciampi E, Uribe-san-martin R, Soler B, et al. Safety and
humoral response rate of inactivated and mRNA vaccines against
SARS-CoV-2 in patients with Multiple Sclerosis [J]. Mult Scler Relat
Disord, 2022 IN-6, 59: 103690.
[22] Ciotti J R, Perantie D C, Moss B P, et al. Perspectives and
experiences with COVID-19 vaccines in people with MS [J]. Multiple
Sclerosis Journal-Experimental Translational and Clinical, 2022 IN-7,
8(1).
[23] Di filippo M, Cordioli C, Malucchi S, et al. mRNA COVID-19
vaccines do not increase the short-term risk of clinical relapses in
multiple sclerosis [J]. J Neurol Neurosurg Psychiatry, 2022 IN-8,
93(4): 448-50.
[24] Dinoto A, Sechi E, Ferrari S, et al. Risk of disease relapse
following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD
and MOGAD [J]. Mult Scler Relat Disord, 2022IN-9, 58: 103424.
[25] Doron A, Piura Y, Vigiser I, et al. BNT162b2 mRNA COVID-19
vaccine three-dose safety and risk of COVID-19 in patients with
myasthenia gravis during the alpha, delta, and omicron waves [J]. J
Neurol, 2022IN-10, 269(12): 6193-201.
[26] Dreyer-alster S, Menascu S, Mandel M, et al. COVID-19
vaccination in patients with multiple sclerosis: Safety and humoral
efficacy of the third booster dose [J]. J Neurol Sci, 2022IN-11,
434: 120155.
[27] Etemadifar M, Abhari A P, Nouri H, et al. Self-Reported safety
of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with
multiple sclerosis [J]. Hum Vaccin Immunother, 2022 IN-12, 18(1):
2041945.
[28] Gamez J, Gamez A, Carmona F. Safety of mRNA COVID-19 vaccines
in patients with well-controlled myasthenia gravis [J]. Muscle
Nerve, 2022 IN-14, 66(5): 612-7.
[29] Giannoccaro M P, Vacchiano V, Leone M, et al. Difference in
safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with
autoimmune neurological disorders: the ANCOVAX study [J]. Journal of
Neurology, 2022 IN-15, 269(8): 4000-12.
[30] Kavosh A, Ashtari F, Naghavi S, et al. Safety of Sinopharm
vaccine for people with Multiple Sclerosis: Study of adverse reactions
and disease activity [J]. Mult Scler Relat Disord, 2022 IN-28, 61:
103708.
[31] Li h Y, Shao L Y, Song M, et al. Safety of inactivated
SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study [J].
Front Immunol, 2022 MG-26, 13: 923017.
[32] Lotan I, Hellmann M A, Friedman Y, et al. Early safety and
tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia
gravis [J]. Neuromuscul Disord, 2022 IN-25, 32(3): 230-5.
[33] Maniscalco G T, Scavone C, Mascolo A, et al. The Safety Profile
of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A
Retrospective Observational Study [J]. Journal of Clinical Medicine,
2022 IN-24, 11(22).
[34] Mariottini A, Bertozzi A, Marchi L, et al. Effect of
disease-modifying treatments on antibody-mediated response to
anti-COVID19 vaccination in people with multiple sclerosis [J].
Journal of Neurology, 2022 IN-23, 269(6): 2840-7.
[35] Peric S, Rankovic M, Bozovic I, et al. COVID-19 infection and
vaccination against SARS-CoV-2 in myasthenia gravis [J]. Acta
Neurologica Belgica, 2022IN-22.
[36] Pincheira A U, Alnajjar S, Katzberg H, et al. Retrospective
study on the safety of COVID-19 vaccination in myasthenia gravis
[J]. Muscle & Nerve, 2022 IN-21, 66(5): 558-61.
[37] Rauber S, Korsen M, Huntemann N, et al. Immune response to
SARS-CoV-2 vaccination in relation to peripheral immune cell profiles
among patients with multiple sclerosis receiving ocrelizumab [J].
Journal of Neurology Neurosurgery and Psychiatry, 2022 IN-20, 93(9):
978-85.
[38] Reyes-leiva D, Lopez-contreras J, Moga E, et al. Immune
Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With
Myasthenia Gravis [J]. Neurol Neuroimmunol Neuroinflamm, 2022 IN-19,
9(4).
[39] Stastna D, Menkyova I, Drahota J, et al. To be or not to be
vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination
and infection [J]. Multiple Sclerosis and Related Disorders, 2022
IN-18, 65.
[40] Trinchillo A, Esposito M, Habetswallner F, et al. COVID19
vaccine in myasthenia gravis patients: safety and possible predictors of
disease exacerbation [J]. Neurol Sci, 2022 IN-17: 1-4.
[41] Rodrigues C L, De freitas H C, Lima P R O, et al. Myasthenia
gravis exacerbation and myasthenic crisis associated with COVID-19: case
series and literature review [J]. Neurol Sci, 2022, 43(4): 2271-6.
[42] Tur C, Dubessy A L, Otero-romero S, et al. The risk of
infections for multiple sclerosis and neuromyelitis optica spectrum
disorder disease-modifying treatments: Eighth European Committee for
Treatment and Research in Multiple Sclerosis Focused Workshop Review.
April 2021 [J]. Mult Scler, 2022, 28(9): 1424-56.
[43] Sriwastava S, Sharma K, Khalid S H, et al. COVID-19 Vaccination
and Neurological Manifestations: A Review of Case Reports and Case
Series [J]. Brain Sci, 2022, 12(3).
[44] Lechner-scott J S, Davis J S, Hawkes C, et al. Vaccine
hesitancy in people with multiple sclerosis [J]. Mult Scler Relat
Disord, 2022, 65: 104102.
[45] Rakusa M, Öztürk S, Moro E, et al. COVID-19 vaccination
hesitancy among people with chronic neurological disorders: A position
paper [J]. Eur J Neurol, 2022, 29(8): 2163-72.
[46] Burki t K. Omicron variant and booster COVID-19 vaccines
[J]. Lancet Respir Med, 2022, 10(2): e17.
[47] Kim S, Jeong S H, Shin H Y, et al. Factors affecting the
intention of COVID-19 vaccination in Korean patients with myasthenia
gravis: A survey-based study [J]. Front Neurol, 2022, 13: 847873.
[48] Yap S M, AL hinai M, Gaughan M, et al. Vaccine hesitancy among
people with multiple sclerosis [J]. Mult Scler Relat Disord, 2021,
56: 103236.
[49] Abbasi N, Ghadiri F, Moghadasi A N, et al. COVID-19 vaccine
hesitancy in Iranian patients with multiple sclerosis [J]. Mult
Scler Relat Disord, 2022, 60: 103723.
[50] Baars A E, Kuitwaard K, De koning L C, et al. SARS-CoV-2
Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory
Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy [J].
Neurology, 2023, 100(2): e182-e91.
Fig 1. PRISMA flow chart depicting the study screening and
selection of the systematic review
Fig 2. Forst maps of General adverse events following COVID-19
vaccination in patients with ANC.
Fig 3. Top-panel: Forst maps of adverse events causing
Neurological symptoms \in ANC patients following COVID-19
vaccination ; bottom panel : Forst maps of causing exacerbation
of disease following COVID-19 vaccination.
Fig 4. Forst maps of causing exacerbation of disease following
COVID-19 vaccination with subtyped for type of ANC.
Fig 5. Forst maps of causing exacerbation of disease following
COVID-19 vaccination with subtyped for type ofvaccine.
Fig 6. Forst maps of causing exacerbation of disease following
COVID-19 vaccination with subtyped for dose of vaccine.
Fig 7. The funnel plot of included studies.
Table.1 Characteristics of included studies.
Abbreviate: ANC: autoimmune neurological conditions; MS :
multiple sclerosis; MG: myasthenia gravis; NMOSD :neuromyelitis optica
spectrum disorder; CI: confidence interval;
Supplementary Figure 1: Pooled incidence of adverse events in
patients with ANC subtyped for type of Symptoms.
Supplementary Figure 2: Adverse events following COVID-19
vaccination in patients subtyped for type of ANC.
Supplementary Figure 3: Adverse events following COVID-19
vaccination in patients with ANC subtyped for dose of vaccine.
Supplementary Figure 4: Adverse events following COVID-19
vaccination in patients with ANC subtyped for type of vaccine.
Supplementary Figure5: Egger’s test for publication bias.
Supplementary Figure 6: Leave one out sensitivity analysis was
performed to re-estimate the pooled incidence rate of adverse events.
Supplementary Table 1: Detailed search strategy for the
systematic review.